日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Construction and validation of acetylation-related gene signatures for immune landscape analysis and prognostication risk prediction in luminal breast cancer.

构建和验证乙酰化相关基因特征,用于免疫景观分析和管腔型乳腺癌预后风险预测

Zhu Mengdi, Lin Jinna, Liu Haohan, Wang Jingru, Liu Nianqiu, Li Yudong, Lai Hongna, Shi Qianfeng

Trastuzumab deruxtecan in an elderly patient with HR+/HER2-low breast cancer complicated by pleural effusion: a case report and literature review

曲妥珠单抗德鲁替康治疗老年HR+/HER2-低表达乳腺癌合并胸腔积液患者:病例报告及文献综述

Huang, Shiyu; Law, Saikam; Chen, Maojian; Lai, Hongna

Global Trend in Research and Development of CDK4/6 Inhibitors for Clinical Cancer Therapy: A Bibliometric Analysis

CDK4/6抑制剂在临床癌症治疗中的研发全球趋势:文献计量分析

Lai, Hongna; Jiang, Wei; Zhao, Jianli; Dinglin, Xiaoxiao; Li, Yudong; Li, Shunying; Wang, Ying; Yao, Herui

Circulating Tumor DNA Predicts the Response and Prognosis in Patients With Early Breast Cancer Receiving Neoadjuvant Chemotherapy

循环肿瘤DNA可预测接受新辅助化疗的早期乳腺癌患者的疗效和预后

Li, Shunying; Lai, Hongna; Liu, Jieqiong; Liu, Yujie; Jin, Liang; Li, Yudong; Liu, Fengtao; Gong, Yuhua; Guan, Yanfang; Yi, Xin; Shi, Qianfeng; Cai, Zijie; Li, Qian; Li, Ying; Zhu, Mengdi; Wang, Jingru; Yang, Yaping; Wei, Wei; Yin, Dong; Song, Erwei; Liu, Qiang

Non-invasive analysis of tumor mutation profiles and druggable mutations by sequencing of cell free DNA of Chinese metastatic breast cancer patients

通过对中国转移性乳腺癌患者游离DNA进行测序,对肿瘤突变谱和可药物靶向突变进行无创分析

Li, Shunying; Wang, Xiaobao; Li, Yuquan; Lai, Hongna; Liu, Yujie; Jin, Liang

Long non-coding RNA CRALA is associated with poor response to chemotherapy in primary breast cancer

长链非编码RNA CRALA与原发性乳腺癌化疗反应不良相关

Li, Yudong; Wang, Baoxiao; Lai, Hongna; Li, Shunying; You, Qiuting; Fang, Yichao; Li, Qian; Liu, Yujie